Trial reportJournal of atherosclerosis and thrombosis2010
Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
Trial report in Journal of atherosclerosis and thrombosis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.Annals of medicine · 2026Article
- Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update.Journal of clinical medicine · 2026Review
- Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review.JACC. Asia · 2025Review
- Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy.Diabetology international · 2025Article
- Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies.Journal of clinical medicine · 2022Review
- Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies.Cardiovascular diabetology · 2022Article
- Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks.Clinical cardiology · 2018Article
- My Approach to the Patient With Familial Hypercholesterolemia.Mayo Clinic proceedings · 2016Review
- Lipoprotein (a): structure, pathophysiology and clinical implications.Arquivos brasileiros de cardiologia · 2014 · on this mapReview
- Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.Heart and vessels · 2013Article
- Do We Know When and How to Lower Lipoprotein(a)?Current treatment options in cardiovascular medicine · 2010Article
- Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study.Current therapeutic research, clinical and experimental · 2010Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEzetimibe is a novel cholesterol absorption inhibitor that reduces the level of low-density lipoprotein (LDL)-cholesterol (C). The effects of ezetimibe on remnant-like particle (RLP)-C, lipoprotein (a) [Lp(a)], and oxidized LDL (Ox-LDL) levels have not been examined.
methodsFifty patients with dyslipidemia were treated with 10 mg/day of ezetimibe. At baseline and 12 weeks after treatment with ezetimibe, we measured the levels of RLP-C, Lp(a), Ox-LDL, and high-sensitivity C-reactive protein (hs-CRP).
resultsThe mean levels of total cholesterol (TC), LDL-C, triglycerides (TG), and apolipoprotein (apo) B, respectively, showed a significant decrease from 229+/-39 to 191+/-37 mg/dL (-16%, p<0.0001), from 151+/-34 to 118+/-33 mg/dL (-22%, p<0.0001), from 162+/-82 to 135+/-55 mg/dL (-7%, p<0.01), and from 116+/-22 to 94+/-21 mg/dL (-18%, p<0.0001) after 12 weeks of treat-ment with ezetimibe. The mean level of RLP-C and median level of hs-CRP also decreased signifi-cantly from 6.8+/-4.0 to 4.8+/-2.5 mg/dL (-21%, p<0.0001) and from 0.6 to 0.4 mg/L (-33%, p<0.05). The median level of Lp(a) decreased significantly from 14 to 10 mg/dL (-29%, p<0.05) in patients treated with ezetimibe monotherapy.
conclusionsEzetimibe was effective for reducing the levels of TC, LDL-C, TG, and RLP-C. Ezeti-mibe could be a potential therapeutic option for decreasing the Lp(a) level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.